Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03459066
Other study ID # Spasticity Factors
Secondary ID
Status Completed
Phase
First received
Last updated
Start date October 1, 2018
Est. completion date October 30, 2020

Study information

Verified date November 2020
Source Universidad de la Frontera
Contact n/a
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

Spasticity is part of the syndrome motor neuron following a Stroke. It is a clinical sign of great complexity that generates disability, limiting the function and altering the quality of life of the subjects, generating great impact on families and society. Identify times and characteristics of appearance; as well as its predictive factors can support an early intervention, orienting and strengthening the work of the rehabilitation team. Determine the times of establishment, location and factors that favor the development of spasticity in acute stage and how it influences the functionality, quality of life and emotional level of post-stroke patients in hospital facilities. Through this proposal, it is proposed to generate a new line of research that allows the development of scientific evidence in the area of neurorehabilitation, specifically in the field of spasticity, through the identification of establishment times, affected structures and predominant patterns in the extremities; as well as determining factors that favor the development of spasticity and its impact on post-stroke functionality and quality of life. This information will strengthen the rehabilitative process of these subjects and the actions of the rehabilitation team, supporting the identification of preventive measures and implementing effective interventions that allow achieving better motor and functional results, in search of an optimal recovery.


Description:

A correlational (non-experimental), longitudinal, prospective follow-up design will be used for descriptive and predictive purposes. The sample will consist of 150 subjects who meet the inclusion criteria, sign the informed consent and who will be treated during the year 2018 at the Hospital and the Clinic. The study will include three measurement times: Time 1, during the first 10 days of hospitalization (T1); Time 2, at 3 months after T1; and Time 3, at 12 months after T1. At each time of measurement, the study variables will be evaluated by 4 professionals trained in the following instruments: the Ashworth Scale to assess spasticity; To measure global functionality, the Barthel Index will be applied and, to assess functionality of the upper extremity, the Action Research Arm scale will be used; The Quality of Life Scale for Stroke-38 will be used to assess quality of life and emotional level. In addition, in time 1 the sociodemographic and clinical characteristics of the sample will be evaluated through a clinical record prepared for this purpose.


Recruitment information / eligibility

Status Completed
Enrollment 100
Est. completion date October 30, 2020
Est. primary completion date March 30, 2019
Accepts healthy volunteers No
Gender All
Age group 20 Years to 80 Years
Eligibility Inclusion Criteria: - Have an age between 20 and 80 years, with no previous history of motor disability. - Being hospitalized with a diagnosis of ischemic or hemorrhagic stroke in the acute period. - Present a history with a single stroke event confirmed by Computerized Axial Tomography. - Without severe cognitive commitment, that is, score greater than 14 on the MiniMental Abbreviated scale. - Stable hemodynamically. - Voluntarily accept participation in the study through the signing of informed consent, either personally or through a family member. Exclusion Criteria: - Present sensitive aphasia. - Have a medical contraindication.

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
Institution-Group
The study includes three measurement times: Time 1 (T1): corresponds to the first measurement, which will take place between the 3rd and 10th day of hospitalization. Time 2 (T2): corresponds to the second measurement, which will be carried out 3 months after the first measurement. Time 3 (T3): corresponds to the third measurement, which will be carried out 12 months after the first measurement. The evaluations will be tone, functionality and quality of life.

Locations

Country Name City State
Chile Universidad de La Frontera Temuco

Sponsors (1)

Lead Sponsor Collaborator
Universidad de la Frontera

Country where clinical trial is conducted

Chile, 

Outcome

Type Measure Description Time frame Safety issue
Primary Ashworth Scale Instrument used in the assessment of spasticity. Graduates the tone from 0 (no increase in tone) to 4 (rigid extremity in flexion or extension), it is based on the examiner manually moving a limb of the patient, in the whole of the possible joint range (in the clinical setting it is use 1 second to perform the complete joint travel) and perceive the resistance that a muscle offers when stretched. 6 months
Primary Action Research Arm This Instrument was constructed to determine the functional recovery of the upper limb. It is composed of 19 items grouped in 4 subtest, including each subtest: 6 items of grip, 4 items taken, 6 items of clip, 3 items of thick movement. All the items are evaluated with a scale of 4 points from 0 to 3, where 0 represents no movement and 3 normal movement for the task. 6 months
Primary Barthel Index Scale that assesses the level of patient independence with respect to performing Activity Daily Life. The values assigned to each activity depend on the time spent and help to carry it out.
The activities are valued differently, being able to assign 0, 5, 10 or 15 points. The global range can vary between 0, completely dependent, and 100 points, completely independent.
6 months
See also
  Status Clinical Trial Phase
Completed NCT04649632 - Relation Between Dose and Time to Reinjection of Botulinum Toxin-A in Patient With Poststroke Spasticity From a Real-world Healthcare Insurance Database.